Latest Period
Q1 2026
Security Snapshot
Applied Therapeutics, Inc. - Common Stock, par value $0.0001 per share (APLT) Institutional Ownership
CUSIP: 03828A101
13F Institutional Holders and Ownership History from Q2 2019 to Q1 2026
Institutions Reporting
0
Shares (Excl. Options)
0
Price
$0.10
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- APLT
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 0
- Total 13F value
- $0
- Share change
- -52,527,047
- Value change
- -$5,294,094
- Number of holders
- 0
- Shares outstanding
- 143,223,667
- SEC-reported price per share
- $0.10
- Insider filing price
- $0.10
Latest holder snapshot
4 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- APLT - Applied Therapeutics, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 03828A101.
- 0 institutions reported positions in Q1 2026.
- 12 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 50 to 0 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $5,929,909 to $0.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 0 institutions filings for Q1 2026.
Security key
03828A101
Latest holder period
Q1 2026
13F holders
0
13D/G owners
12
CIK / CUSIP context first
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 03828A101:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
12
Security
APLT
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 15% | +13% | $12,946,856 | +$1,644,911 | 21,403,300 | +15% | T. Rowe Price Investment Management, Inc. | 30 Sep 2025 |
| Alyeska Investment Group, L.P. | 5.8% | $2,615,924 | 6,707,497 | Alyeska Investment Group, L.P. | 31 Dec 2024 | |||
| ALEXANDRIA REAL ESTATE EQUITIES, INC. | 4.3% | $1,755,000 | 6,500,000 | Alexandria Real Estate Equities, Inc. | 11 Dec 2025 | |||
| Propel Bio Management, LLC | 4.2% | $1,564,002 | 6,015,394 | Propel Bio Management, LLC | 29 Dec 2025 | |||
| Venrock Healthcare Capital Partners III, L.P. | 4.1% | -58% | $2,171,407 | -$2,432,661 | 5,567,709 | -53% | Venrock Healthcare Capital Partners III, L.P. | 31 Mar 2025 |
| BlackRock, Inc. | 3.7% | -54% | $1,003,183 | -$783,523 | 5,219,475 | -44% | BlackRock, Inc. | 30 Jun 2025 |
| VANGUARD GROUP INC | 3.3% | -34% | $1,473,225 | -$359,492 | 4,734,013 | -20% | The Vanguard Group | 30 Jun 2025 |
| Schonfeld Strategic Advisors LLC | 3.3% | -53% | $1,823,678 | -$1,596,482 | 4,676,097 | -47% | Schonfeld Strategic Advisors LLC | 31 Mar 2025 |
| PERCEPTIVE ADVISORS LLC | 2.4% | $1,115,400 | 2,860,000 | Perceptive Advisors LLC | 31 Dec 2024 | |||
| MORGAN STANLEY | 2.5% | -64% | $1,114,983 | -$2,323,072 | 2,858,931 | -68% | Morgan Stanley | 31 Jan 2025 |
| FRANKLIN RESOURCES INC | 1.7% | -70% | $781,326 | -$1,871,029 | 2,003,400 | -71% | Franklin Resources, Inc. | 31 Dec 2024 |
| JANUS HENDERSON GROUP PLC | 0% | -104% | $13,958 | -$4,706,957 | 35,791 | -100% | JANUS HENDERSON GROUP PLC | 31 Dec 2024 |
As of 31 Mar 2026, 0 institutional investors reported holding 0 shares of Applied Therapeutics, Inc. - Common Stock, par value $0.0001 per share (APLT). This represents 0% of the company’s total 143,223,667 outstanding shares.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
28
Latest
Q1 2026
Rows shown
1-25 of 28
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 0 | $0 | -$5,294,094 | $0.10 | 0 |
| 2025 Q4 | 58,883,039 | $5,929,909 | -$23,764,068 | $0.10 | 50 |
| 2025 Q3 | 94,763,328 | $57,199,408 | +$5,274,176 | $0.60 | 69 |
| 2025 Q2 | 88,058,885 | $27,371,087 | -$7,459,469 | $0.31 | 72 |
| 2025 Q1 | 106,044,815 | $51,845,704 | -$6,334,916 | $0.49 | 89 |
| 2024 Q4 | 115,065,005 | $98,537,797 | -$63,025,089 | $0.86 | 116 |
| 2024 Q3 | 112,721,874 | $960,819,113 | +$78,176,113 | $8.50 | 125 |
| 2024 Q2 | 103,226,978 | $481,702,267 | +$36,985,908 | $4.67 | 92 |
| 2024 Q1 | 93,958,967 | $638,614,949 | +$241,302,453 | $6.80 | 88 |
| 2023 Q4 | 61,449,532 | $205,844,085 | +$29,840,415 | $3.35 | 83 |
| 2023 Q3 | 42,970,428 | $106,996,842 | +$29,101,733 | $2.49 | 54 |
| 2023 Q2 | 31,465,661 | $40,275,555 | +$15,796,729 | $1.28 | 38 |
| 2023 Q1 | 19,276,965 | $15,634,509 | -$232,317 | $0.81 | 34 |
| 2022 Q4 | 19,679,561 | $15,064,959 | -$2,201,503 | $0.76 | 37 |
| 2022 Q3 | 22,671,560 | $21,085,673 | -$3,749,758 | $0.93 | 38 |
| 2022 Q2 | 26,706,667 | $25,318,845 | +$12,989,524 | $0.95 | 46 |
| 2022 Q1 | 12,347,239 | $26,037,310 | -$34,487,329 | $2.11 | 68 |
| 2021 Q4 | 14,922,342 | $133,548,279 | -$7,772,547 | $8.95 | 67 |
| 2021 Q3 | 15,108,904 | $250,903,236 | -$6,255,939 | $16.60 | 66 |
| 2021 Q2 | 15,367,633 | $319,342,764 | +$10,194,603 | $20.78 | 68 |
| 2021 Q1 | 14,854,223 | $278,593,752 | +$51,374,327 | $18.76 | 66 |
| 2020 Q4 | 12,104,777 | $266,428,658 | -$1,610,604 | $22.01 | 67 |
| 2020 Q3 | 12,195,771 | $253,182,315 | -$6,258,655 | $20.76 | 66 |
| 2020 Q2 | 11,427,491 | $412,583,649 | +$78,213,106 | $36.15 | 71 |
| 2020 Q1 | 9,645,977 | $315,329,165 | +$155,281,170 | $32.69 | 62 |